GLP2R and inflammatory bowel disease: The anti-inflammatory and intestinal growth effects mediated by glepaglutide, coupled with the exclusive localization of the GLP-2R in the gastrointestinal tract, make this peptide an interesting therapeutic candidate for treatment of IBD.